Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Evolent Health, Inc.NYSE: EVH
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $13.63M, compared with -$28.71M a year earlier. Trailing-twelve-month EBITDA was -$314.51M.
Context
- EBITDA amounted to 19.3% of revenue in FY2025, up 15.9 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of $182.75M (+150.6%) for the fiscal year ending Dec 2026, a step up from the -525.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $13.63M+103.7% QoQ
- Last fiscal yearDec 2025
- -$361.31M-525.8% YoY
- LTMMar 2026
- -$314.51M-1056.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +147.5% | +143.4% | -4.1 pp |
| 1 year | -525.8% | +150.6% | +676.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (361.31M) USD
- Year-over-year change
- -525.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (361.31M) | -525.8% |
| FY2024 | 2024-12-31 | 84.85M | +442.4% |
| FY2023 | 2023-12-31 | (24.79M) | -156.7% |
| FY2022 | 2022-12-31 | 43.75M | -21.4% |
| FY2021 | 2021-12-31 | 55.66M | — |
EBITDA vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 EBITDA of -$314.51M is the 10th highest of the 11 companies compared; the peer median is -$90.62M.
- Its year-over-year change of -1056.6% is the lowest of 11, against a peer median of -15.3%.
- EBITDA amounts to 16.7% of revenue for EVH, versus a peer median of 52.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $291.89M | +36.3% | — | 33.2% | |
| LTM Mar 2026 | $201.6M | +416.8% | -49.5% | 5.9% | |
| LTM Mar 2026 | $69.88M | +7.2% | +7.6% | 22.4% | |
| LTM Mar 2026 | -$66.72M | -25.2% | — | 64.8% | |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$145.24M | -14.0% | — | — | |
| LTM Mar 2026 | -$292.27M | -64.2% | — | 408.0% | |
| LTM Dec 2025 | -$311.38M | -33.2% | — | — | |
| LTM Mar 2026 | -$314.51M | -1056.6% | — | 16.7% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| Peer median (excluding EVH) | -$90.62M | -15.3% | -20.9% | 52.6% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Cost of Revenue | 657.55M | 1.04B | 1.5B | 2.19B | 1.59B |
| Gross Profit | 250.41M | 316.58M | 460.47M | 367.35M | 284.03M |
| Gross Margin | 27.6% | 23.4% | 23.4% | 14.4% | 15.1% |
| Research & Development | 0 | 27M | 0 | 0 | 0 |
| Selling, General & Admin | 219.5M | 269.27M | 358.11M | 263.05M | 288.47M |
| Operating Expenses | 292.82M | 312.94M | 531.68M | 407.84M | 288.47M |
| Depreciation & Amortization | 60.04M | 90.25M | 123.42M | 123.17M | 115.85M |
| EBITDA | 55.66M | 43.75M | (24.79M) | 84.85M | (361.31M) |
| EBITDA Margin | 6.1% | 3.2% | -1.3% | 3.3% | -19.3% |
| Operating Income | (42.41M) | 3.64M | (71.21M) | (40.49M) | (4.44M) |
| Operating Margin | -4.7% | 0.3% | -3.6% | -1.6% | -0.2% |
| Interest Income | 407K | 1.37M | 5.26M | 5.54M | 4.19M |
| Interest Expense | 25.43M | 15.57M | 54.21M | 24.72M | 57.47M |
| Other Income / Expenses | 12.61M | (65.72M) | (131.19M) | (22.55M) | (530.2M) |
| Income Before Tax | (29.8M) | (62.08M) | (202.41M) | (63.04M) | (534.64M) |
| Pre-Tax Margin | -3.3% | -4.6% | -10.3% | -2.5% | -28.5% |
| Income Tax Expense | 483K | (43.38M) | (89.37M) | (1.41M) | (126K) |
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (534.51M) |
| Net Margin | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
| EPS (Basic) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| EPS (Diluted) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| Weighted Avg Shares | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Weighted Avg Shares (Diluted) | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.